🔎 Trials Near Me

Home › Hepatoblastoma

Hepatoblastoma clinical trials recruiting in the U.S.

11 studies for Hepatoblastoma are recruiting participants at sites across the United States.

Cities with the most studies

By state

Recently updated studies

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119

Molecular Basis of Pediatric Liver Cancer

RecruitingObservational study
Ages 0 to 99 · All sexes · Updated Aug 10, 2026 · NCT03959800

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

RecruitingPhase 1/2
Ages 1 to 21 · All sexes · Updated Jul 6, 2026 · NCT04634357

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

RecruitingPhase 1
Up to age 21 · All sexes · Updated May 19, 2026 · NCT04897321

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated May 19, 2026 · NCT04901702

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Apr 15, 2026 · NCT04308330

Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative

RecruitingObservational study
All ages · All sexes · Updated Mar 18, 2026 · NCT05556642

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

RecruitingPhase 2
Ages 1 to 50 · All sexes · Updated Mar 13, 2026 · NCT01804634

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

RecruitingPhase 1
Up to age 21 · All sexes · Updated Nov 3, 2025 · NCT06198296

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.